JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph has maintained an Overweight rating on Monte Rosa Therapeutics (NASDAQ:GLUE) but lowered the price target from $31 to $11.
October 19, 2023 | 7:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
JP Morgan has maintained an Overweight rating on Monte Rosa Therapeutics but lowered the price target from $31 to $11.
The lowering of the price target by JP Morgan, a major financial institution, could negatively impact investor sentiment towards Monte Rosa Therapeutics, potentially leading to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100